Boc-L-Tyr(2-Br-Z)-OH

Boc-L-Tyr(2-Br-Z)-OH is a protected L-tyrosine derivative designed for peptide and medicinal-chemistry synthesis, featuring a Boc-protected amino group and a tyrosine side chain bearing a 2-bromo substituent. The side-chain phenolic functionality is masked as a Z-protected group, providing controlled reactivity during coupling and downstream transformations. This reagent is commonly selected when brominated tyrosine analogs are needed for halogen-based structure-activity relationship work, radiolabeling precursor workflows, or late-stage functional diversification of peptide scaffolds.

1. Brominated Peptide Building Block

Boc-L-Tyr(2-Br-Z)-OH is used by peptide synthesis groups to prepare peptide segments that incorporate a brominated tyrosine residue with orthogonal side-chain protection. The Boc amino protection supports standard protected-amino-acid coupling workflows, while the Z-masked phenolic group helps maintain side-chain integrity during assembly. Researchers developing halogenated peptide libraries for SAR studies often choose this specific tyrosine derivative to introduce a defined 2-bromo substitution pattern at the aromatic ring, enabling systematic evaluation of halogen effects on conformation, binding-site interactions, and chemical reactivity in subsequent derivatization steps.

2. Medicinal Chemistry SAR Intermediates

Boc-L-Tyr(2-Br-Z)-OH serves as a practical intermediate for medicinal chemistry programs that require brominated tyrosine analogs as building blocks toward peptidomimetics and tyrosine-based pharmacophore variants. The protected amino functionality and masked phenol allow controlled elaboration in multistep synthesis, supporting workflows where the bromine substituent is retained for further substitution, cross-coupling, or conversion into other aryl-functional groups. Medicinal chemistry teams frequently rely on this type of protected bromotyrosine derivative to streamline the preparation of analog series while reducing side reactions associated with free phenolic and amino groups.

3. Radiolabeling Precursor Development

Boc-L-Tyr(2-Br-Z)-OH is commonly positioned for precursor development where aryl bromides provide a handle for downstream labeling strategies and tracer synthesis workflows. The presence of a defined bromine at the 2-position on the tyrosine aromatic ring supports late-stage diversification routes that can be adapted to radiochemistry or non-radioactive tracer analog generation, depending on the downstream conversion chemistry. Chemical biology and radiotracer development teams often select a protected bromotyrosine derivative to keep functional groups controlled during precursor assembly, improving reproducibility when preparing defined aryl-brominated intermediates for labeling campaigns.

4. Late-Stage Aromatic Functionalization

Boc-L-Tyr(2-Br-Z)-OH is used when a brominated tyrosine motif is required as a platform for later aromatic functionalization after peptide or intermediate assembly. The protected amino and masked phenol help avoid premature side reactions, while the 2-bromo substituent provides a chemically addressable site for subsequent substitution or coupling-based diversification. This makes the reagent attractive for researchers building complex, functionalized scaffolds where the brominated aromatic ring acts as a strategic intermediate, allowing controlled introduction of additional substituents only at the stage that best matches purification and analytical verification needs.

1. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment

2. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

3. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

4. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

5. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients